Oxford International, Le Montreux Palace, Montreux, Switzerland
06-08 June 2006
In keeping with Oxford International’s highly successful drug discovery series, an expert panel of speakers will convene to lead a full conference programme of more than 15 case study presentations, allowing attendees to gain an essential industry update.
* STRATEGY:
Integrating a translational approach to drug discovery: bridging the gap between discovery and development
* TECHNOLOGIES:
The emerging importance of –omics technologies: genomics, proteomics, metabolomics, pharmacogenomics
Integrating predictive technologies such as biomarkers, HTS within discovery
Optimising lead generation and validation
Taking different approaches to discovery: employing structural biology and medicinal chemistry methodologies
* INFORMATION MANAGEMENT:
Achieving interoperability and integrating informatics, chem- and bio-informatics within discovery
Handling multi-source data and integrating diverse IT solutions
Knowledge Management
* PRODUCTIVITY:
Consolidating the discovery and development process: cutting costs, increasing efficiencies and maximising productivity
* PORTFOLIO MANAGEMENT:
Strategically managing the discovery portfolio: the business case for emerging technologies and achieving interoperability
|
|
|
Invited Speakers:
|
|
Confirmed Speakers: * Dr. Ismail Kola, Senior Vice President, Basic Research, Merck & Co.
* Dr. Michel Pairet, Senior Vice President Research, Boehringer-Ingelheim Pharma GmbH & Co KG
* Dr. Jeremy Everett, Vice President, Medical Technologies, Pfizer
* Dr. Silvio Albertini, Deputy Head, Toxicology, F. Hoffmann-La Roche Ltd.
* Dr. Greg Wiederrecht, Vice President and Head, External Scientific Affairs, Merck Research Labs
* Dr. Chas Bountra, VP and Head of Biology, Neurology and GI Centre of Excellence for Drug Discovery, GlaxoSmithKline
* Dr. Deborah Hartman, Director, Lead Generation, AstraZeneca
* Dr. Kimber Hardy, Director, R&D Portfolio Management, Serono
* Dr. Ulf Boemer, Head Technology Development & HTS Infrastructure, Schering AG
* Dr. Sam Wadsworth, Vice President, Translational Research, Genzyme Pharmaceuticals
* Dr. Wilma Keighley, Senior Director, Discovery Technologies, Pfizer
* Dr. Juergen Hammer, Global Head Research IM; Head of Research Informatics, Genetics and Genomics, F. Hoffmann-La Roche
* Dr. Steven Muchmore, Group Leader, Structural Biology, Abbott Laboratories
* Senior Representative, Chemical Synthesis Services
* Senior Representative, Invitrogen
|
|